PRMT5 and anemia (phenotype): First-generation PRMT5 inhibitors enteringclinical trials wereeither SAM competitive (JNJ-64619178 and PF-06939999) or SAM uncompetitive(GSK3326595 and EPZ015666) (Figure 1).18−21 However, concerns regarding dose-limiting side effects such as anemia,thrombocytopenia, and neutropenia were apparent.22,23 Consequently, several PRMT5 ligands acting via different mechanisms(e.g., proteolysis targeting chimeras) are being investigated as potentialcancer therapeutics.12